Compare GRF & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | NSRX |
|---|---|---|
| Founded | 1989 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 38.9M |
| IPO Year | N/A | 2024 |
| Metric | GRF | NSRX |
|---|---|---|
| Price | $10.33 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 4.0K | ★ 10.6K |
| Earning Date | 01-01-0001 | 03-25-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $1.98 |
| 52 Week High | $11.85 | $9.50 |
| Indicator | GRF | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 48.24 |
| Support Level | $9.69 | $2.90 |
| Resistance Level | $10.64 | $3.60 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 51.97 | 45.74 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.